Journal of Genetic Syndromes & Gene Therapy
Open Access

RNA Guided Epigenetic Regulation Strategies for Chromosomal Dosage Disorders

Meera Kulkarni^{* *}Correspondence: Meera Kulkarni, Department of Cytogenetics, Western Institute of Biomedical Sciences, Pune, India, Email:

Author info »

Description

Chromosomal dosage disorders arise when cells carry an altered number of chromosomal segments or experience abnormal gene copy distribution across specific regions of the genome. These alterations may occur through deletions, duplications, translocations, or mosaic chromosomal arrangements. The resulting imbalance in gene expression affects multiple developmental systems, often leading to neurodevelopmental differences, structural anomalies, and altered physiological regulation across tissues. Because these conditions originate from changes in gene quantity rather than single gene defects, conventional single-target interventions provide limited correction at the molecular level [1].

In chromosomal duplication conditions, excessive gene expression from duplicated segments can disrupt developmental signaling networks. Experimental models suggest that controlled repression of overexpressed regions may restore partial balance in cellular protein levels. RNA-guided platforms utilize engineered binding sequences that identify specific genomic loci and recruit transcriptional suppressor complexes [2]. These complexes can reduce transcriptional activity of selected genes, lowering excessive protein production toward physiologically tolerable ranges. Conversely, in deletion-based disorders where gene copies are missing, compensatory activation strategies have been investigated. Certain genes possess inactive or low-activity paralogs that can be stimulated to increase expression. RNA-guided activator systems are designed to attract transcriptional enhancement complexes to promoter regions of these backup gene copies. This approach allows partial restoration of functional protein levels without introducing external genetic material [3].

Cell-type specificity plays a significant role in determining therapeutic outcomes in chromosomal dosage conditions. Different tissues may respond differently to gene imbalance, with neural and cardiac tissues often showing higher sensitivity to dosage variations. This variability has led researchers to design regulatory systems driven by tissue-specific promoter environments. By aligning regulatory activity with cellular identity markers, expression modulation can be confined to affected tissues while minimizing unintended influence on unaffected regions [4]. One area of experimental focus involves syndromes associated with partial trisomy conditions, where segments of a chromosome are present in three copies instead of the usual two. In neuronal models derived from patient stem cells, RNA-guided suppression of duplicated gene clusters has been associated with partial normalization of synaptic protein distribution. Electrophysiological recordings indicate improved consistency in neuronal signaling patterns following modulation of overexpressed genes. Although full correction is not achieved, observed cellular stabilization suggests that dosage adjustment can influence functional outcomes [5].

In monosomy-related conditions, where a chromosomal segment is missing, researchers have investigated epigenetic activation of silent genomic regions. Some genes within the genome exist in a low-expression state under normal conditions but retain the capacity for increased transcription under specific regulatory influence [6]. Ribonucleic Acid (RNA)-guided recruitment of histone acetylation complexes has been used to increase chromatin openness at targeted loci. This change promotes higher transcriptional output from partially functional gene networks, contributing to partial restoration of protein levels.

Epigenetic memory is another important factor in long-term regulation. Once chromatin states are altered, cells may retain these patterns through subsequent divisions. This property can be beneficial when sustained regulation is desired, but it may also lead to unintended persistence of regulatory changes. Studies in cell culture systems show that removal of regulatory complexes does not always restore original expression states immediately, suggesting that secondary maintenance pathways preserve chromatin configuration [7].

Pediatric chromosomal dosage disorders present additional considerations due to ongoing development and tissue maturation. Early intervention may influence developmental trajectories, particularly in neurological systems undergoing active synapse formation and pruning. However, developmental plasticity also introduces variability in response to regulatory interventions. Long-term observation in animal models indicates that timing of intervention can influence both magnitude and stability of gene expression adjustment. In cardiac-related dosage disorders, altered gene expression may affect structural development of heart tissue and electrical conduction systems. Experimental modulation of dosage-sensitive genes in cardiomyocyte cultures has shown changes in contraction rhythm consistency and calcium handling efficiency [8]. These findings suggest that regulated expression adjustment may influence physiological stability in tissues with high metabolic demand.

Single-cell genomic profiling has provided insight into cellular heterogeneity within dosage disorder tissues. Not all cells exhibit identical expression imbalance, with some cells compensating through natural regulatory mechanisms. This heterogeneity suggests that partial correction in a subset of cells may be sufficient to produce measurable systemic improvement. Understanding this distribution has influenced design strategies that prioritize targeted modulation rather than uniform genome-wide adjustment. Another area of development involves reversible regulation systems that allow gene expression adjustments to be turned on or off depending on physiological requirements [9]. Small molecule-responsive control elements can be integrated into RNA-guided systems, enabling external regulation of activity. This allows fine adjustment of gene expression levels over time, which may be useful in conditions where developmental stages require different expression balances [10].

Conclusion

Future research directions include development of multi-locus regulatory systems capable of simultaneously adjusting multiple chromosomal regions. Such systems may be particularly relevant in complex syndromes involving several dosage-sensitive genes. Additional exploration is also focused on improving delivery specificity to target affected tissues while minimizing exposure to non-target regions. Continued progress in RNA-guided epigenetic regulation research indicates expanding potential for managing chromosomal dosage disorders at the expression level. While challenges remain in precision control and long-term stability, ongoing refinement of regulatory design, delivery systems, and computational prediction methods supports further advancement in this area of genetic medicine.

References

1. L. Seritan A, Ortigas M, Seritan S, A. Bourgeois J, J. Hagerman R. Psychiatric disorders associated with FXTAS. Curr Psychiatry Rev. 2013;9(1):59-64.

   [Crossref] [Google Scholar] [PubMed]

2. Subramanyam AA, Mukherjee A, Dave M, Chavda K. Clinical practice guidelines for autism spectrum disorders. Indian J Psychiatry. 2019;61(Suppl 2):254-269.

   [Crossref] [Google Scholar] [PubMed]

3. Bush L, Davidson H, Gelles S, Lea D, Koehly LM. Experiences of families caring for children with newborn screening-related conditions: Implications for the expansion of genomics in population-based neonatal public health programs. Int J Neonatal Screen. 2022;8(2):35.

   [Crossref] [Google Scholar] [PubMed]

4. Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, et al. ECCO guidelines on the prevention, diagnosis and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021;15(6):879-913.

   [Crossref] [Google Scholar] [PubMed]

5. Hotta A. Genome editing gene therapy for Duchenne muscular dystrophy. J Neuromuscul Dis. 2015;2(4):343-355.

   [Crossref] [Google Scholar] [PubMed]

6. Allen D, Knop O, Itkowitz B, Kalter N, Rosenberg M, Iancu O, et al. CRISPR-Cas9 engineering of the RAG2 locus via complete coding sequence replacement for therapeutic applications. Nat Commun. 2023;14(1):6771.

   [Crossref] [Google Scholar] [PubMed]

7. Dinculescu A, Link BA, Saperstein DA. Retinal gene therapy for Usher syndrome: current developments, challenges and perspectives. Int Ophthalmol Clin. 2021;61(4):109-124.

   [Crossref] [Google Scholar] [PubMed]

8. Keeler AM, Flotte TR. Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are we and how did we get here?. Annu Rev Virol. 2019;6(1):601-621.

   [Crossref] [Google Scholar] [PubMed]

9. Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 2017;4(2):43-63.

   [Crossref] [Google Scholar] [PubMed]

10. Bourgeois JA, Farzin F, Brunberg JA, Tassone F, Hagerman P, Zhang L, et al. Dementia with mood symptoms in a fragile X premutation carrier with the fragile X-associated tremor/ataxia syndrome: clinical intervention with donepezil and venlafaxine. J Neuropsychiatry Clin Neurosci. 2006;18(2):171-177.

    [Crossref] [Google Scholar] [PubMed]